Volastra Therapeutics is a biotechnology company that develops small molecule drugs for the treatment of cancer and other diseases. The company's lead drug candidate is a first-in-class inhibitor of a protein called STING, which plays a key role in the immune response to cancer. Volastra's drug is designed to activate the immune system to attack cancer cells and improve patient outcomes. The company was founded in 2020 and is headquartered in Cambridge, Massachusetts.